Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
37 authors.
Chloe L Bowman *Cancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0002-0517-706X
Colin J Daniel *Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0008-1915-3660
Eric J CarlsonCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-1217-0563
Vidhi M ShahDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-7934-978X
Amy S FarrellDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0008-4599-5423
Kayleigh M KresseDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-7949-248X
Xiaoyan WangDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0006-9559-9221
Kyra A LindleyCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0009-5734-6292
Madeline R KuhnCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-7157-3389
Kevin MacPherson-HawthorneDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-2657-8762
Brittany L Allen-PetersenDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-7436-9412
Jennifer EngDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-1499-8417
Motoyuki TsudaDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-2873-1449
Isabel A EnglishDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0566-9585
Carl PelzDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-2235-880X
Arslan AmerCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-3290-0017
Aaron R DoeCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-6650-2001
Megan A TurnidgeDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0008-1241-4864
Zina P JennyDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0008-9434-4299
Trent WaughBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0001-0874-1482
Zinab O DohaDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-2952-9840
Nicholas D KendserskyDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0007-5586-8308
Kristof TorkenczyDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-4869-7957
Katherine R PelzDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-2169-0613
Andrew J FieldsDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0853-8054
Gabriel M CohnDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-5901-2506
Gabrielle S DewsonDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0874-0607
Mary C ThomaDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-6856-9282
Taylor S AmeryDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0008-5007-4952
Mara H ShermanBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-7826-3888
Koei ChinCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-8061-7462
Anupriya AgarwalCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-8319-6162
Jason M LinkBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-6892-0431
Brett C SheppardBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-2182-7547
Andrew C AdeyCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-7648-8717
Rosalie C SearsDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-1558-2413
Ellen M LangerCancer Early Detection Advanced Research (CEDAR) Center, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-0352-1859
Funding
Understanding the Impact of Microscale and Nanoscale Heterogeneity and ResistanceU54CA209988 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HEISER, LAURA MADELINE · 2017 to 2021
$10.3M
Hydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
The Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0M
American Cancer Society (ACS) RSG-22-060-01-MMCancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University (CEDAR)NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NCI NIH HHS U01 CA224012NCI NIH HHS U54 CA209988
6 · The paper itself
Abstract
The prolyl isomerase PIN1 is overexpressed in cancer and contributes to cancer cell-intrinsic phenotypes, including proliferation and migration. However, PIN1 may also function in stromal cells within the tumor microenvironment. In this study, we showed that PIN1 is a critical regulator of pancreatic stellate cell (PSC) state at baseline and in response to the myofibroblast-activating factor TGFβ. Loss or inhibition of PIN1 altered the epigenetic and transcriptional responses of PSCs to TGFβ, preventing PSC differentiation to a myofibroblast state and altering expression of secreted matrix proteins and signaling molecules. Consistent with inhibition of the TGFβ response, low fibroblast PIN1 expression in mouse and human pancreatic ductal adenocarcinoma correlated with low expression of αSMA, a marker of myofibroblast activation. Decreased PIN1 expression at baseline also altered paracrine hepatocyte growth factor (HGF) signaling from fibroblasts to tumor cells. PSCs with low PIN1 expression displayed reduced expression and secretion of HGF, resulting in an attenuation of c-MET receptor phosphorylation and signaling in nearby cancer cells. In allograft models, host PIN1 was critical for normal growth of a subset of pancreatic cancer cell lines that are responsive to HGF signaling. Through the identification of changes to fibroblast activation state and cross-talk following PIN1 loss or inhibition, these data suggest that systemic targeting of PIN1 will suppress the protumorigenic pancreatic ductal adenocarcinoma microenvironment and may differentially affect heterogeneous patient populations. SIGNIFICANCE: PIN1 plays a critical role in the response of pancreatic stellate cells to TGFβ and can be targeted to attenuate myofibroblast activation and protumor cross-talk to suppress pancreatic cancer progression.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. · full record | OpenQuestion